Drugs / VEGFR1

Trials 11 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 16 trials
Phase 1 NCT00874588 Mar 2009 → Jun 2012 non-small cell lung carcinoma Fukushima Medical University Completed No outcome recorded
Phase 1 NCT00791570 Oct 2008 → Apr 2012 wet macular degeneration Osaka University Completed No outcome recorded
Phase 1 NCT01266720 Apr 2008 → Mar 2010 malignant pancreatic neoplasm Fukushima Medical University Unknown No outcome recorded
Phase 1 NCT00632333 Feb 2008 → Dec 2011 esophageal cancer Teikyo University Unknown No outcome recorded
Phase 1 NCT00561275 Oct 2007 → May 2008 esophageal cancer Japanese Foundation for Cancer Research Completed No outcome recorded
Phase 1 NCT00633724 May 2007 → Jun 2012 non-small cell lung carcinoma Fukushima Medical University Completed No outcome recorded
Phase 1/25 trials
Phase 1/2 NCT00677287 May 2008 → Mar 2009 colon carcinoma, rectal cancer Tokyo University Terminated No outcome recorded
Phase 1/2 NCT00681577 May 2008 → Oct 2009 gastric cancer Tokyo University Completed No outcome recorded
Phase 1/2 NCT00681421 May 2008 → Apr 2009 esophageal cancer Tokyo University Completed No outcome recorded
Phase 1/2 NCT00673777 May 2008 → Apr 2009 non-small cell lung carcinoma Tokyo University Unknown No outcome recorded
Phase 1/2 NCT00681252 May 2008 → Apr 2009 gastric cancer Tokyo University Completed No outcome recorded

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 11 sources stand behind the page.

FieldValueCited text
Known as VEGFR1 ClinicalTrials.gov intervention name — accepted as the source's own label NCT00791570
9

NCT00633724

NCT00632333

NCT00681421

NCT00681577

NCT00874588

NCT00681252

NCT00561275

NCT00677287

NCT00673777

Known as VEGFR1, VEGFR2 ClinicalTrials.gov intervention name — accepted as the source's own label NCT01266720
Modality Peptide “VEGFR1 peptide(1mg)” NCT00673777
Route Subcutaneous “the URLC10 peptide (1mg), VEGFR1 peptide (1mg) and VEGFR2 peptide (1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection” NCT00681252
Target VEGFR1 “Vascular endothelial growth factor receptor 1 (VEGFR1) and vascular endothelial growth factor receptor 2 (VEGFR2) are essential targets for tumor angiogenesis.” NCT00632333